A Multicentre, Observational, Phase 4 Study to Evaluate the Safety and Tolerability of Lenvatinib in Patients with Advanced or Unresectable Hepatocellular Carcinoma (STELLAR).

Datos básicos

Código:
E7080-M000-508
Protocolo:
E7080-M000-508
EUDRACT:
NCT:
Centro:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Dotación:
Año de incio:
2021
Año de finalización:
2024
ESTUDIO OBSERVACIONAL

Documentos

  • No hay documentos

Participantes

Grupos

Financiadores - Promotores

EISAI EUROPE LTD

Resultados del Ensayo Clínico


A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer.

Okuno, Keisuke; (...); Goel, Ajay

Letter. 10.1186/s12943-022-01699-2. 2023

  • Open Access.

CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG-STS 1001 study

Frezza, Anna Maria; (...); Gronchi, Alessandro

Article. 10.1002/cam4.5015. 2022

  • Open Access.

Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: A Feasibility Analysis of Electronic Health Records Using Natural Language Processing.

Ortiz A; (...); Rodriguez M

Article. 10.1159/000528784. 2023

  • Open Access.

Concordance of baseline RAS mutational status (ms) between tissue and cell-free DNA (cfDNA) and association with overall response rate (ORR) in first-line (1L) metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study (cohort 2) (NCT02792478)

Valladares-Ayerbes, M; (...); Vila, AL

Meeting Abstract. 10.1016/j.annonc.2021.08.976. 2021

  • Open Access.

Correction: Update on the management of elderly patients with colorectal cancer.

Soler-González G; (...); Gironés-Sarrió R

Correction. 10.1007/s12094-023-03351-x. 2024

  • Open Access.

Characteristics and outcomes of advanced melanoma patients with complete response and elective discontinuation of first-line anti-programmed death-1 monotherapy: A real-world multicentre observational cohort study.

Ochenduszko, Sebastian; (...); Maiques, Inmaculada Maestu

Article. 10.1111/pcmr.13093. 2023

  • Open Access.

Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning.

Munoz, Andres J.; (...); Hernandez-Presa, Miguel Angel

Article. 10.1016/j.thromres.2023.06.015. 2023


Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?

Contreras-Toledo, Debora; (...); Carmona-Bayonas, Alberto

Article. 10.1038/s41416-023-02563-w. 2024


Encorafenib (E) plus binimetinib (B) in unresectable advanced or metastatic BRAFV600-mut melanoma, real-world evidence in Spain (GEM 2002-BECARE)

Soria, A.; (...); Cerezuela-Fuentes, P.

Meeting Abstract. 10.1016/j.annonc.2023.09.2248. 2023

  • Open Access.

European Association of Urology (EAU) Testicular Cancer Guidelines Panel: A new prognostic factor risk group classification for patients with clinical stage 1 seminoma in active surveillance.

Boormans, Joost; (...); Laguna, Pilar

Meeting Abstract. 2023


Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study.

Valladares-Ayerbes M; (...); Lloansí Vila A

Article. 10.3390/cancers14246075. 2022

  • Open Access.

First in human trial of CEB-01 for retroperitoneal soft tissue sarcoma

Gonzalez, J. A.; (...); Lopez Pousa, A.

Meeting Abstract. 10.1016/j.annonc.2023.09.1161. 2023

  • Open Access.

First-line chemotherapy with or without targeted therapies in metastatic colorectal cancer: The GEMCAD 14-01 prospective cohort

Oliveres, H.; (...); Maurel, J.

Meeting Abstract. 10.1016/j.annonc.2023.09.1796. 2023


ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma

Martin Broto, Javier; (...); Hindi, Nadia

Meeting Abstract. 2023


Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial.

Gonzalez-Cao M; (...); Berrocal A

Article. 10.1038/s41467-021-26572-6. 2021

  • Open Access.

Intracranial activity of encorafenib and binimetinib followed by radiotherapy in patients with BRAF mutated melanoma and brain metastasis: Preliminary results of the GEM1802/EBRAIN-MEL phase II clinical trial

Marquez-Rodas, I; (...); Berrocal, A

Meeting Abstract. 10.1016/j.annonc.2021.08.1423. 2021

  • Open Access.

Maintenance of angiogenesis inhibition with aflibercept after progression to bevacizumab in metastatic colorectal cancer: real life study in the Valencian community.

Raga, Mireia Gil; (...); Hernandez, Isabel Busquier

Article. 10.1007/s12094-022-03047-8. 2023


Multicenter real-world data of treatment with NALIRI plus 5FU/LV in advanced Spanish pancreatic cancer

Alvarez Gallego, R.; (...); Cubillo, A.

Meeting Abstract. 10.1016/j.annonc.2023.04.238. 2023


Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).

Gronchi, Alessandro; (...); Casali, Paolo Giovanni

Article. 10.1200/JCO.23.00908. 2024


Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.

Pasquali, Sandro; (...); Gronchi, Alessandro

Article. 10.1002/cncr.33895. 2022

  • Open Access.

Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG), and the Polish Sarcoma Group (PSG).

Gronchi, Alessandro; (...); Casali, Paolo Giovanni

Meeting Abstract. 2022


Pancreatic cancer, Radiomics and Artificial Intelligence: A Review.

Marti-Bonmati L; (...); Alberich-Bayarri A

Article. 10.1259/bjr.20220072. 2022


Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).

Broto, Javier Martin; (...); Hindi, Nadia

Meeting Abstract. 2022


Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning.

Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel

Meeting Abstract. 2022


Predicting recurrence of venous thromboembolism in anticoagulated cancer patients using real-world data and machine learning.

Martin, Andres J. Munoz; (...); Hernandez-Presa, Miguel Angel

Meeting Abstract. 2022


Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.

Boormans, Joost L; (...); Laguna, M Pilar

Article. 10.1016/j.euo.2023.10.014. 2023


Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01)

Aparicio, Jorge; (...); Maurel, Joan

Article. 10.1007/s12094-022-02868-x. 2022

  • Open Access.

Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

Aparicio, J; (...); Maurel, J

Meeting Abstract. 10.1016/j.annonc.2021.08.937. 2021

  • Open Access.

Real-world study on characteristics of advanced melanoma patients with sustained complete response (CR) after elective 1st line anti-programmed death-1 (anti-PD1) monotherapy discontinuation.

Ochenduszko, Sebastian; (...); Maestu, Inmaculada

Meeting Abstract. 2022


Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

Gonzalez-Cao, Maria; (...); Berrocal, Alfonso

Meeting Abstract. 10.1200/JCO.2021.39.15_suppl.9528. 2021


Retrospective real-world data study using natural language processing to describe treatment sequence and clinicopathological patterns in patients with metastatic colorectal cancer in five Spanish institutions

Vera Garcia, R.; (...); Mondejar Solis, R.

Meeting Abstract. 10.1016/j.annonc.2023.04.343. 2023

  • Open Access.

RT after Encorafenib and Binimetinib on BRAF mutated melanoma brain metastases. GEM1802-Phase II

Alvarez, A.; (...); Marquez Rodas, I.

Meeting Abstract. 2023


Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.

Gounder, Mrinal M.; (...); Attia, Steven

Article. 10.1200/JCO.21.01829. 2022

  • Open Access.

SEOM-GEMCAD-TTD clinical guidelines for the systemic treatment of metastatic colorectal cancer (2022).

Fernandez Montes, Ana; (...); Aparicio, Jorge

Article. 10.1007/s12094-023-03199-1. 2023

  • Open Access.

Update on the management of elderly patients with colorectal cancer.

Soler-Gonzalez, Gemma; (...); Girones-Sarrio, Regina

Article. 10.1007/s12094-023-03243-0. 2023

  • Open Access.

Venous thromboembolism recurrence during anticoagulant treatment in gastrointestinal cancer patients

Munoz Martin, A.; (...); Angel Hernandez-Presa, M.

Meeting Abstract. 2022


Campos de estudio

Compartir